Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine effect on Deucravacitinib PK in healthy males
NCT03419910Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum concentration at 24 hours and Area under the concentration vs time curve from time zero to 24 hours post dose. Started Mar 2018; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03419910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419910.